Become MergersCorp Agent | Book a Virtual Meeting | 出售业务 |

- 简体中文

is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.

This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States

The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom

Return to Listings

获得许可的瑞士药品批发业务

描述

温特图尔, 瑞士

Business ID: L#20250834

这家拥有药品批发许可证的企业是制药行业的先驱，致力于通过创新的医疗保健解决方案提高生活质量。公司成立的愿景是满足尚未得到满足的医疗需求，在研发方面堪称楷模，专注于开发治疗罕见和复杂疾病的独特疗法。

在瑞士注册的药品批发商拥有瑞士医药公司颁发的宝贵的 “良好分销规范”（GDP）授权。该公司拥有全面的药品批发许可证，可以开展国内和国际贸易业务，包括进出口和原材料批发活动。该公司在温特图尔的总部只有一个小团队，其业务结构是为全球医药市场服务。

战略价值定位
公司的主要资产是其 GDP 许可证，它是进入药品批发行业的重要壁垒。迄今为止的投资总额为 230,566.18 瑞士法郎，包括完整的运行设置和监管合规。该企业提供灵活的收购结构，可选择融资全购。

瑞士制药业与税收优惠
瑞士制药业是首屈一指的全球中心，是行业领袖的故乡，并以其卓越的质量和监管而闻名于世。获得许可的企业可从这一著名的生态系统中获益，在这里，医药产品可获得溢价，并可轻松进入欧盟和全球市场。瑞士的监管框架虽然严格，但通过与主要市场签订相互承认协议，为国际贸易业务提供了极大的便利。

从税收角度来看，瑞士为制药业务提供了令人信服的优势。该国的企业税率是欧洲最具竞争力的税率之一，通常在 11.9% 到 21.6% 之间，具体取决于各州。瑞士的专利盒制度允许对专利相关收入进行优惠征税，对符合条件的收入给予高达 90% 的税收减免。此外，企业还可享受研发超级减免和知识产权的节税处理。瑞士税收制度的稳定性和透明度，加上广泛的避免双重征税条约网络，为国际医药贸易和投资创造了最佳环境。

GDP 授权的范围涵盖全面的药品批发业务，使收购方能够立即进入受监管的药品分销行业。虽然目前还没有收入，但已建立的监管框架和运营基础设施为进入瑞士和国际药品批发市场提供了交钥匙解决方案。